This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Heartfailure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heartfailure with reduced ejection fraction is more common. fold higher risk of heartfailure with preserved ejection fraction (95% CI 1.30 m/s had a 2.10-fold m/s had a 2.10-fold
Bicuspid aorticvalve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration. We performed repair of the rupture and concomitant ascending aorta replacement to prevent further exacerbation of the patient's condition.
A 70-year-old female patient with a history of bioprosthetic aorticvalve replacement and coronary artery bypass graft presented with bioprosthetic valvefailure secondary to prosthetic valve endocarditis. This resulted in early death due to myocardial infarction and acute heartfailure.
Heartfailure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aorticvalve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Photo courtesy of Mount Sinai Health System milla1cf Thu, 02/22/2024 - 13:47 February 22, 2024 — Ismail El-Hamamsy , MD, PhD, Director of Aortic Surgery for the Mount Sinai Health System and the Mount Sinai Randall B. The aorticvalve controls blood flow from the heart into the aorta, the main artery that feeds blood to most of the body.
Background Closure of paravalvular leak (PVL) regurgitation after self-expandable (SE) transcatheter aorticvalve implantation (TAVI) may be more challenging than after balloon-expandable (BE) valve implantation. The patient was deemed to be at prohibitive surgical risk and a catheter-based PVL closure procedure was planned.
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heartfailure and moderate aortic stenosis (stage B aortic stenosis).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aorticvalve replacement (TAVR) in the treatment of heartfailure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aorticvalve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Circulation.
1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aorticvalve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. tim.hodson Wed, 09/04/2024 - 15:53 Sept.
The Most Common Form of HVD One of the most prevalent and serious forms of heartvalve disease is aortic stenosis (AS), a condition characterized by the narrowing of the aorticvalve opening, which affects approximately 5% of adults over 65a number expected to more than double by 2050.
TAVR in heartfailure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heartfailure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes.
Edwards Lifesciences is going all-in on structural heart and heartfailure, acquiring aorticvalve-maker JenaValve Technology and implantable heartfailure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
milla1cf Tue, 04/23/2024 - 15:53 April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management.
Getty Images milla1cf Thu, 06/13/2024 - 20:38 June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. More specifically, the Avalus Ultra surgical valve has: A low valve profile designed to facilitate ease of use at implant.1,2
Journal of the American Heart Association, Ahead of Print. BackgroundThe coexistence of transthyretin cardiac amyloidosis (ATTRCA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. P=0.003) but not heartfailure hospitalization (HR, 1.1 [95% 95% CI, 1.11.4];P<0.0001)
Objective The association between a combined anaemia and renal failure index and 1-year prognosis of patients undergoing transcatheter aorticvalve implantation (TAVI) is unexplored. The primary clinical outcome measure was all-cause mortality and heartfailure hospitalisation 1 year after TAVI. 95% CI 2.21
(MedPage Today) -- CHICAGO -- Dapagliflozin (Farxiga) lowered mortality and heartfailure worsening in high-risk older adults getting transcatheter aorticvalve implantation (TAVI), the DapaTAVI trial showed. In a population with a history of.
Clinical introduction A woman in her 60s with non-obstructive coronary artery disease, aorticvalve replacement and aortic arch repair, chronic diastolic heartfailure and paroxysmal atrial fibrillation (AF) and flutter (AFL), presented with 3 days of sustained palpitations that felt similar to prior episodes of AF/AFL.
Journal of the American Heart Association, Ahead of Print. BackgroundLp(a) (lipoprotein(a)) is an independent risk factor for calcific aorticvalve stenosis (CAVS). Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events is unknown.
New-onset persistent left bundle branch block (NOP-LBBB) at discharge after transcatheter aorticvalve replacement (TAVR) is frequent but its association with death and hospitalization for heartfailure (HHF) remains unclear.
Backgrounds Permanent pacemaker implantation (PPMI) is one of the greatest disadvantages of transcatheter aorticvalve implantation (TAVI). Methods We retrospectively analysed data from 745 consecutive patients who underwent TAVI for severe aortic stenosis from November 2013 to July 2022. vs 9.1%±9.7%; p=0.035).
This study aimed to confirm the prognostic value of a novel angiographic microvascular resistance (AMR) index in patients undergoing transcatheter aorticvalve replacement.Methods and ResultsWe prospectively included 335 patients with severe aortic stenosis who underwent transcatheter aorticvalve replacement at Fuwai Hospital.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. JenaValve presented positive results of its U.S.
Proposed approach for clinical management and therapeutic optimization in patients with heartfailure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.
Joint Statement on AorticValve Replacement in Low-Risk Patients Issued by Society of Thoracic Surgeons and European Association for Cardiothoracic Surgeons 6. STOP-CA Clinical Trial Finds Statins Lower Rate of Heart Decline in Lymphoma Patients, Late-Breaking ACC23 Clinical Trial Reports 7.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aorticvalve replacement (TAVR) System compared to surgical aorticvalve replacement (SAVR) and other TAVR valves.
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter AorticValve Replacement (TAVR). milla1cf Tue, 12/26/2023 - 21:36 December 26, 2023 — MindMics, Inc. the R&D Manager of MindMics.
BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Over a follow-up of up to 5 years, severe MR correlated with higher all-cause mortality (P=0.02) and aorticvalve replacement rates (P=0.012).
Objectives This study aimed to evaluate the prognostic value of coronary microvascular dysfunction (CMD) at long term after transcatheter aorticvalve implantation (TAVI) and to explore its relationship with extravalvular cardiac damage (EVCD). CMD was defined as IMR angio ≥30 units.
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
The prognostic value of this updated classification after transcatheter aorticvalve implantation (TAVI) is unknown. Methods 579 consecutive patients treated by TAVI with preprocedural right heart catheterisation evaluation were included. We also analysed the prognostic role of residual postprocedural PH.
This report delineates two instances of AAV with large arterial involvement, one case presenting with lesions of the aorticvalve and the other with lesions of the pulmonary artery. The patient's aorticvalve thickening virtually disappeared after treatment with hormones combined with immunosuppressive agents.
Stress hyperglycemia ratio (SHR) has recently been recognized as a novel biomarker that accurately reflects acute hyperglycemia status and is associated with poor prognosis of heartfailure. We evaluated the r.
HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations, cardiac catherizations, transcatheter aorticvalve replacements, balloon and coronary angioplasties and more. It’s an honor to have the U.S.’s
We know that structural heart disease and heartfailure are the leading causes of hospitalization and morbidity in the U.S. Standalone performance for significant major valve disease pathology (aortic stenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.
Assessment of fluid overload identifies aortic stenosis (AS) patients at high risk and treatment of fluid overload may potentially improve the post-interventional clinical course. TAVI, transcatheter aorticvalve implantation. Hospitalization for heartfailure (HHF) and/or death served as primary endpoint.
Objectives The management of severe aortic stenosis mandates consideration of aorticvalve intervention for symptomatic patients. However, for asymptomatic patients with severe aortic stenosis, recent randomised trials supported earlier intervention. to 0.96; I 2 15%). to 0.56; I 2 77%).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content